| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Laboratory of Molecular Pharmacology, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland 20205
The DNA sequence selectivities of guanine-N7 alkylation produced by three chloroethylating antitumor agents, 1-(2-chloroethyl)-3-(cis-2-hydroxy) cyclohexyl-1-nitrosourea (cis-2-OH CCNU), 2-chloroethyl (methylsulfonyl)methanesulfonate, and 8-carbamoyl-3-(2-chloroethyl)imidazo-[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (mitozolomide), were examined using a modification of the Maxam and Gilbert sequencing technique. In a region of pBR322 DNA, 2-chloroethyl (methylsulfonyl)methanesulfonate produced approximately the same degree of alkylation at all guanines. cis-2-OH CCNU, however, preferentially alkylated the middle guanines in runs of three or more guanines; the intensity of the reaction increased with the number of adjacent guanines in the DNA sequence. Mitozolomide produced the same pattern of preferential alkylation but not as intensely as cis-2-OH CCNU. Three other nitrosoureas, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, 1-(2-fluorethyl)-3-cyclohexyl-1-nitrosourea, and 1-(2-chloroethyl)-1-nitrosourea gave similar patterns of alkylation to that of cis-2-OH CCNU at pH 7.2. The ratio of 7-hydroxyethylguanine to 7-chloroethylguanine was approximately the same following treatment of the synthetic polymers dGm·dCm and (dG·dC)m with cis-2-OH CCNU, indicating that 7-chloroethylation and 7-hydroxyethylation were enhanced similarly by the presence of adjacent guanines. Ethylnitrosourea produced relatively little alkylation preference. The results suggest that the alkylating intermediates, 2-chloroethyldiazohydroxide and 2-hydroxyethyldiazohydroxide, tend to react preferentially with those guanine-N7 positions the electronegativity of which is enhanced by the presence of neighboring guanines. This is consistent with the presence of cationic character in the alkylating centers of these intermediates. 2-Chloroethyl (methylsulfonyl)methanesulfonate and ethyldiazohydroxide would not be expected to have strong cationic character, in agreement with their lack of sequence selectivity.
1 To whom requests for reprints should be addressed, at Laboratory of Molecular Pharmacology, Developmental Therapeutics Program, Division of Cancer Treatment, Building 37, Room 5A19, 9000 Rockville Pike, Bethesda, MD 20205.
Received 8/19/85. Revised 12/31/85. Accepted 1/ 2/86.
This article has been cited by other articles:
![]() |
M. E. Loghin, M. D. Prados, P. Wen, L. Junck, F. Lieberman, H. Fine, K. L. Fink, M. Metha, J. Kuhn, K. Lamborn, et al. Phase I Study of Temozolomide and Irinotecan for Recurrent Malignant Gliomas in Patients Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study Clin. Cancer Res., December 1, 2007; 13(23): 7133 - 7138. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ganguly, F. Wang, M. Kaushik, M. P. Stone, L. A. Marky, and B. Gold A study of 7-deaza-2'-deoxyguanosine 2'-deoxycytidine base pairing in DNA Nucleic Acids Res., September 25, 2007; 35(18): 6181 - 6195. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Gatto, S. Richter, S. Moro, G. Capranico, and M. Palumbo The topoisomerase II poison clerocidin alkylates non-paired guanines of DNA: implications for irreversible stimulation of DNA cleavage Nucleic Acids Res., October 15, 2001; 29(20): 4224 - 4230. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. P. Spiro, L. Liu, S. Majka, J. Haaga, J. K. V. Willson, and S. L. Gerson Temozolomide: The Effect of Once- and Twice-a-Day Dosing on Tumor Tissue Levels of the DNA Repair Protein O6-Alkylguanine-DNA-Alkyltransferase Clin. Cancer Res., August 1, 2001; 7(8): 2309 - 2317. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Matheson, J. McNamee, and B. J. Jean-Claude Design of a Chimeric 3-Methyl-1,2,3-triazene with Mixed Receptor Tyrosine Kinase and DNA Damaging Properties: A Novel Tumor Targeting Strategy J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 832 - 840. [Abstract] [Full Text] |
||||
![]() |
W. R. Mancini, E. R. Glaze, P. L. Stetson, and H. S. Greenberg Sensitization of 1,3-bis(2-Chloroethyl)-1-nitrosourea and Cisplatin Cytotoxicity by 5-Bromo-2'-deoxyuridine in Human Glioma J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1404 - 1409. [Abstract] [Full Text] |
||||
![]() |
A. Inga, F.-X. Chen, P. Monti, A. Aprile, P. Campomenosi, P. Menichini, L. Ottaggio, S. Viaggi, A. Abbondandolo, B. Gold, et al. N-(2-Chloroethyl)-N-nitrosourea Tethered to Lexitropsin Induces Minor Groove Lesions at the p53 cDNA That Are More Cytotoxic than Mutagenic Cancer Res., February 1, 1999; 59(3): 689 - 695. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Baker, M. Wirth, P. Statkevich, P. Reidenberg, K. Alton, S. E. Sartorius, M. Dugan, D. Cutler, V. Batra, L. B. Grochow, et al. Absorption, Metabolism, and Excretion of 14C-Temozolomide following Oral Administration to Patients with Advanced Cancer Clin. Cancer Res., February 1, 1999; 5(2): 309 - 317. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |